PACS Group (PACS) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue grew 29% year-over-year to $981.8 million, with adjusted EBITDA up 77% to $99.7 million, reflecting strong operational execution and expansion.

• Achieved strong financial and operational performance, with high occupancy rates and 75% of skilled nursing portfolio at 4- or 5-star CMS QM ratings.

• Completed major acquisitions, including 28 additional facilities post-Q2 and the Prestige transaction, expanding the footprint to 276 facilities in 15 states.

• Completed IPO in April 2024, raising $414.2 million in net proceeds, with $90.9 million in IPO-related stock-based compensation impacting Q2 net income.

• Operates over 220 facilities across 9 states as of June 30, 2024, serving over 22,000 patients daily and supported by ~35,000 employees.

Financial highlights

• Q2 2024 revenue: $981.8 million, up 29.1% year-over-year; six-month revenue: $1.92 billion, up 30.5%.

• Q2 2024 adjusted EBITDA: $99.7 million, up from $56.4 million in Q2 2023; six-month adjusted EBITDA: $188.2 million.

• Q2 2024 GAAP net loss of $10.9 million, primarily due to $90.9 million in IPO-related stock-based compensation.

• Cash and available liquidity as of June 30, 2024: $413.8 million; cash and cash equivalents: $73.4 million.

• Total facility occupancy was 91% in Q2, with mature facilities at 94.2% occupancy and a 4.3 average QM star rating.

Outlook and guidance

• 2024 annual revenue guidance raised to $3.85–$3.95 billion, a midpoint increase of 25% over 2023.

• 2024 adjusted EBITDA guidance set at $370–$380 million.

• Management expects continued revenue growth through acquisitions and operational improvements, with robust M&A pipeline and sufficient liquidity for at least the next 12 months.

• Medicaid rate growth modeled at 2–2.5% annually, with recent state increases expected to support near-term growth.